相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule
Erika Nordberg et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody
Weibo Cai et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels
R Wild et al.
MOLECULAR CANCER THERAPEUTICS (2006)
An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution
XK Sun et al.
BIOMACROMOLECULES (2005)
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
T Mukohara et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
SF Wong
CLINICAL THERAPEUTICS (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes
CA Boswell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Epidermal growth factor receptor: a promising target in solid tumours
JJ Laskin et al.
CANCER TREATMENT REVIEWS (2004)
Preparation and biological evaluation of copper-64-labeled Tyr3 -: Octreotate using a cross-bridged macrocyclic chelator
JE Sprague et al.
CLINICAL CANCER RESEARCH (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Assessment of epidermal growth factor receptor with Tc-99m-ethylenedicysteine-C225 monoclonal antibody
NR Schechter et al.
ANTI-CANCER DRUGS (2003)
A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor
KA Vallis et al.
NUCLEAR MEDICINE COMMUNICATIONS (2002)
Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
DJ Buchsbaum et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
The epidermal growth factor receptor: A new target for anticancer therapy - Introduction
PAS Johnstone
CURRENT PROBLEMS IN CANCER (2002)
Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains
XX Wen et al.
BIOCONJUGATE CHEMISTRY (2001)
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver
LA Bass et al.
BIOCONJUGATE CHEMISTRY (2000)
分享论文
